CSL Seqirus in North Carolina is working with the U.S. government to manufacture bird flu antigens that can be converted into finished doses. The hosts discuss the financial incentives for pharmaceutical companies to secure government contracts for pandemic response. They mention "Triangle Pharmaceuticals" as a potential player in the burgeoning bird flu industrial complex.
